Bulletin
Investor Alert

Topics

Flu

Video

WSJ Opinion: Joe Biden's Super State

  • WSJ Opinion: Joe Biden's Super State WSJ Opinion: Joe Biden's Super State 5:42
    The Science Behind How the Coronavirus Affects the Brain The Science Behind How the Coronavirus Affects the Brain 7:20
    WSJ Opinion: How the U.S. Fast-Tracked Covid Vaccines WSJ Opinion: How the U.S. Fast-Tracked Covid Vaccines 8:16
    Hospitals in Dakotas Prep for Post-Thanksgiving Jump in Covid Patients Hospitals in Dakotas Prep for Post-Thanksgiving Jump in Covid Patients 4:23
5:35 a.m. March 5, 2021 - MarketWatch.com
For just $25 billion, the U.S. could jump-start a project to quickly vaccinate the entire world against COVID A crash program to increase manufacturing and distribution could save millions of lives and prevent economic disaster.
4:41 a.m. March 5, 2021 - By Andrew Keshner
'I’ve been ready for this since this was declared a pandemic': J&J's one-shot COVID-19 vaccine is enticing for people who hate needles‘Trypanophobia’ is an extreme fear of needles. Approximately 16% of adult patients skipped flu shots because of their needle fears, one study said
7:00 a.m. March 4, 2021 - By MarketWatch
Buy this dip in Apple, Microsoft and these other tech stocks before they’re out of reach, says analystIt’s been a bad week for tech stocks. The Nasdaq tumbled 2.7% on Wednesday and the slide looks set to continue on Thursday. So buy the dip before tech stocks move at least 25% higher this year, says veteran tech analyst Daniel Ives of investment firm Wedbush.
4:00 a.m. March 4, 2021 - By MarketWatch
Buy this dip in Apple, Microsoft and these other tech stocks before they’re out of reach, says analystIt’s been a bad week for tech stocks. The Nasdaq tumbled 2.7% on Wednesday and the slide looks set to continue on Thursday. So buy the dip before tech stocks move at least 25% higher this year, says veteran tech analyst Daniel Ives of investment firm Wedbush.
11:52 a.m. March 3, 2021 - Barrons.com
Oscar Health, Backed by Josh Kushner, Falls Below Its IPO Price The insurtech, which raised $1.4 billion with its initial public offering, began trading on Wednesday.
4:00 a.m. March 3, 2021 - By MarketWatch
Here’s the problem the Fed is fueling — and it’s not inflation, strategist saysOne strategist says the Fed's determination to keep interest rates low through quantitative easing is fueling another problem — it's limiting bank lending.
3:22 p.m. March 2, 2021 - By Kerry Hannon
How to bounce back from COVID-19 career setbacksIt's never too late to turn things around
9:56 a.m. March 2, 2021 - Barrons.com
Oscar Health IPO Could Raise as Much as $1.18 Billion Innovage Holding is another healthcare company set to go public this week.
2:17 p.m. March 1, 2021 - Barrons.com
Novavax Hopes to Start Supplying Covid Shots This Spring The vaccine developer aims to supply 2 billion doses a year.
7:45 a.m. March 1, 2021 - Barrons.com
Perrigo Stock Is Soaring Because of a Deal. Its CEO Says More Good News Is Coming. Perrigo agreed to sell its generic-drug business. CEO Murray Kessler says the company is "reborn again," and will focus on consumer self-care products.
6:16 a.m. March 1, 2021 - By Alicia H. Munnell
Has COVID-19 really affected life expectancy? Many died in 2020-2021, but hopefully it is a one-shot event Many died in 2020-2021, but hopefully it is a one-shot event
4:00 a.m. March 1, 2021 - By MarketWatch
Bitcoin is at a ‘tipping point’ between mainstream boom and speculative implosion. Citi says one is more likelyCiti analysts said we could see a "massive transformation" of cryptocurrency into the mainstream.
10:30 a.m. Feb. 27, 2021 - By Jacob Passy
Federal judge says CDC’s eviction moratorium is unconstitutional, but advocates argue that renters are still protectedThe nationwide eviction ban remains in effect for now, but the judge could issue an injunction in the future.
9:16 a.m. Feb. 25, 2021 - MarketWatch.com
Republican leader of Michigan Senate says Capitol riot was a hoax and 'the far left' is trying to 'cancel' him The state Senate's majority leader, Mike Shirkey, having issued and stood by a false claim that the central role of supporters of then-President Donald Trump in the deadly U.S. Capitol riot was a "hoax," is now claiming to be a victim of leftists seeking to "cancel" him and other Michigan Republicans.
6:38 a.m. Feb. 25, 2021 - By Jaimy Lee
Only 50 people are known to have contracted COVID-19 more than once — but new strains have medical experts on high alertIt’s very rare for someone to get infected with COVID-19 a second time, but the few confirmed cases of reinfection tell us that immunity to the virus isn’t guaranteed and vaccines could become a regular part of our medical care going forward.
10:54 a.m. Feb. 24, 2021 - Barrons.com
Lysol Maker RB Posts Record Annual Sales on Strong Demand for Disinfectant. The Stock Is Up. The FTSE 100 company behind Nurofen and Durex also said it had sold its Scholl footcare brand to U.S. private-equity firm Yellow Wood Partners.
10:57 a.m. Feb. 23, 2021 - By Tonya Garcia
CVS says it will reach millions of new customers as it administers COVID vaccineCVS Health Inc. is looking forward to the chance to meet tons of new shoppers in the coming months as it administers the COVID-19 vaccine, offering the pharmacy retailer a unique business opportunity.
8:52 a.m. Feb. 22, 2021 - Barrons.com
Oscar Health Could Raise $1 Billion in IPO Next Week It's a relatively quiet time for initial public offerings. Only the insuretech, backed by Josh Kushner, is scheduled to make its trading debut next week.
3:17 a.m. Feb. 22, 2021 - MarketWatch.com
COVID-19 is on the run --- expect the pandemic to be under control by Memorial Day This can happen even though many Americans may not be vaccinated by the end of summer.
3:01 a.m. Feb. 22, 2021 - Barrons.com
Sanofi and GlaxoSmithKline Start Phase 2 Trial of Delayed Covid-19 Vaccine The start of the Phase 2 trial comes amid growing concerns over Covid-19 variants. Sanofi said it has also begun development work to address those versions.
1:30 a.m. Feb. 22, 2021 - Barrons.com
How Top Real Estate Fund Managers Are Preparing for a Post-Covid World E-working could kill offices the same way e-commerce killed malls.
11:57 a.m. Feb. 21, 2021 - MarketWatch.com
Biden administration poised to dramatically ramp up coronavirus vaccinationsThe act of delivering injections will soon be the dominant constraint, and it's prompting the Biden administration to push to dramatically expand the universe of those who will deliver injections and where Americans will meet them to get their shots.
9:10 a.m. Feb. 19, 2021 - By Myra P. Saefong
Copper prices top $4 a pound for the first time in over 9 yearsCopper futures top $4 a pound on Friday for the first time since 2011, with expectations for a global economic recovery and a rise in renewable energy sources lifting the metal's demand outlook.
3:14 a.m. Feb. 19, 2021 - Barrons.com
Novavax Unveils Potentially Huge Deal to Supply Vaccines The 1.1 billion-dose commitment includes a previously announced agreement with the Serum Institute of India. Still, the stock was up 10% on Friday morning.
7:30 a.m. Feb. 18, 2021 - By Mark Hulbert
The S&P 500's trailing 12-month return is about to soarU.S. stock market's decline in February and March of 2020 soon won't show up in 12-month results.
4:29 a.m. Feb. 17, 2021 - Barrons.com
Vir and GSK Will Collaborate on Flu Therapy GlaxoSmithKline and Vir Biotechnology will collaborate to develop the same type of treatments for flu that they have made for Covid-19.
3:10 a.m. Feb. 17, 2021 - By Jaimy Lee
Vir, GSK ink new R&D deal Shares of Vir Biotechnology Inc. were up 12.8% in premarket trading on Wednesday after the company said it would expand its research agreement with GlaxoSmithKline to include the flu and other respiratory diseases. As part of the deal, GSK will pay Vir $225 million upfront and will make an equity investment of $120 million in the biotech; it also has the option to develop one drug for $300 million, with the possibility of an additional $200 million in milestone payments. The companies had initially engaged in a deal in 2020 that is focused on studying treatments for coronaviruses, including SARS-CoV-2. One experimental COVID-19 treatment that the companies are already developing is VIR-7831, which is being tested in Phase 3 studies as a monotherapy and in a mid-stage trial as a combination therapy. Vir's stock has soared 287.7% over the past 12 months, while the broader S&P 500 is up 16.%.
4:38 a.m. Feb. 16, 2021 - Barrons.com
CVS Stock Is Climbing Because Covid-19 Testing Bolstered Earnings Covid-19 testing lifted results at CVS Health's pharmacy business, even as the pandemic weighed on nonprescription sales.
4:47 a.m. Feb. 15, 2021 - MarketWatch.com
The U.S. is getting plenty of COVID-19 vaccines, but you still won't have a normal summerThe goal remains herd immunity, and that means more than 242 million people vaccinated.
8:02 a.m. Feb. 13, 2021 - Barrons.com
How the Pandemic Is Changing the Vaccine Industry Annual Covid-19 booster shots are likely, which would lift sales. And the crisis has enabled biotech upstarts to compete with the giants.
5:45 p.m. Feb. 12, 2021 - By Meera Jagannathan
Just 0.5% of U.S. companies mandate COVID-19 vaccination for all employeesThe U.S. Equal Employment Opportunity Commission issued guidance suggesting that employers can mandate COVID-19 vaccines --- with certain conditions.
10:25 a.m. Feb. 10, 2021 - MarketWatch.com
A third of U.S. adults are skeptical of the COVID-19 vaccines, poll findsAbout 1 in 3 Americans say they definitely or probably won’t get the COVID-19 vaccine, according to a new poll that some experts say is discouraging news if the U.S. hopes to achieve herd immunity and vanquish the outbreak.
9:34 a.m. Feb. 10, 2021 - By Ciara Linnane
WHO team member hits back at criticism of Wuhan mission as global COVID tally tops 107 millionA member of the World Health Organization team that traveled to the Chinese city of Wuhan to investigate the origins of the coronavirus pandemic hit back at criticism of the mission from the U.S. State Department, suggesting the former administration was "disengaged" and out of touch.
4:00 a.m. Feb. 10, 2021 - By MarketWatch
Stocks aren’t in a bubble, but here’s what is, according to fund manager Cathie WoodThe manager of the ARK Innovation ETF points the bubble accusation at another asset class.
3:05 a.m. Feb. 10, 2021 - Barrons.com
Annual Covid-19 Boosters May Be Needed, J&J CEO Says Investors haven’t uniformly given companies that have developed vaccines credit for the possibility they could be a long-term source of revenue.
1:48 p.m. Feb. 9, 2021 - By Mike Murphy
Expect to get COVID-19 shots for years to come, Johnson & Johnson CEO saysIn an interview with CNBC, CEO Alex Gorsky said mutations of the coronavirus will necessitate changes to vaccines, much like annual flu shots.
10:03 a.m. Feb. 9, 2021 - MarketWatch.com
Ex-Wisconsin pharmacist pleads guilty to COVID vaccine tamperingA former Wisconsin pharmacist pleaded guilty Tuesday in federal court to charges that he tried to spoil dozens of vials of COVID-19 vaccine.
8:33 a.m. Feb. 9, 2021 - Barrons.com
Sanofi CEO on the Future of Messenger RNA Vaccines — and His Company Shares of biotechs focused on messenger RNA—the technology used for the two Covid-19 vaccines approved in the U.S.—have taken off.
6:02 a.m. Feb. 9, 2021 - MarketWatch.com
9 pandemic trends that may stick around as part of our future routineWhile long earrings will re-emerge, some COVID-19 changes—like increased use of telehealth,—will likely become a regular part of our everyday survival guide.
9:38 a.m. Feb. 6, 2021 - Barrons.com
Josh Kushner-Backed Oscar Health to Seek IPO The insurtech has filed to raise $100 million, according to a prospectus.
Browse topics:

Filter results by

Location

Us (356)

Asia Pacific (62)

Europe (49)

China (48)

Eu (39)

Latin America (10)

Link to MarketWatch's Slice.